![]() Many, perhaps even most, of these companies will not be around in 5 years time. This will make life easier for psychedelic investors, as at the moment we have more than 50 publicly traded psychedelic stocks. For example, Core One Labs (CSE: COOL) (OTC: CLABF) announced that they are looking for someone to finance them or acquire them, as they are having problems funding their operations. In the coming months I expect to see more, perhaps many more, of such deals being announced. This represents more than 10% of the combined costs of the two companies. Given this paradigm, an obvious solution is for companies to combine resources and share costs.įor example, in this acquisition, Numinus and Novamind predict that they will be able to save an estimated $3 million annually, through elimination of duplicated roles. This means that many companies do not have market caps high enough for them to sustainably dilute themselves to fund millions or tens of millions in annual research and staffing costs. Unfortunately, we are at a moment when many psychedelic stocks are low, as pessimism and fear of volatility run high. As I discussed in a video for The Psychedelic Investor, entitled Top 5 Psychedelics Milestones In 2021 & What To Expect in 2022, mergers and acquisitions in this space are likely to be a theme of 2022. While it is possible that this deal coul fall through, it is unlikely.įor investors in psychedelic stocks, this news should not come as a surprise. These steps, however, are likely just formalities. That is expected to happen in June of this year, following the shareholders of both companies approving the measure, and several regulatory procedures being completed. To be clear, this merger is not yet 100% finalized. If this trend line continues into the future, Numinus will double their revenues in approximately 1.5 years. When looking at the two companies’ combined revenue over the past 4 quarters, it has grown by an average of 11.8% quarter over quarter. ![]() On top of this, the recent revenue growth is impressive. This will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability. Perhaps most impressive, the combined company’s revenues will be just shy of $10 million, and they will have more than $56 million in the bank. The combined company, operating under the Numinus’ name and leadership team, will operate 13 wellness clinics across North America, four research sites, and one bioanalytical laboratory. The company has eight ketamine clinics throughout the USA, and they announced recently that they will be hosting a Usona Phase 2 clinical trial treating Major Depressive Disorder with psilocybin-therapy and a MindMed Phase 2b trial treating Generalized Anxiety Disorder with LSD therapy. Novamind, while much smaller with a market cap just shy of $15 million (CAD), is also a leader in certain respects. They have a market cap north of $100 million (CAD), are working with MAPS on treating PTSD with MDMA-therapy, they’re running a compassionate access trial treating Substance Use Disorders with psilocybin-therapy, they’re operating five therapy clinics in Canada, and they have two research facilities and a bioanalytical laboratory. When the transaction is finalized, each Novamind share you own will automatically be transformed into 0.84 of a Numinus share.Įven before the acquisition, Numinus was already a top 10 player in the psychedelic medicines field. If you currently hold Novamind stock, you do not need to do anything. Elon Musk Excites Psychedelic Industry CEOs with This Tweet
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |